ClinicalTrials.gg
RecruitingNCT07460362Updated Mar 10, 2026

Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma

A Phase 2 interventional study of Glofitamab and Lenalidomide in MCL and Relapsed or Refractory Mantle Cell Lymphoma (MCL), sponsored by Peking University Third Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-10.

Primary conditionLymphoma, Mantle-CellRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Mantle-Cell
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Lymphoma, Mantle-Cell.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Peking University Third Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing glofitamab in Lymphoma, Mantle-Cell — 11 open to participants now, 12 under way, none of them phase 3. glofitamab · Lymphoma, Mantle-Cell.

Planned enrollment
4th of 13
43 · median 40
Started
2025
with 2 others
Phase 2
9 of 13
8 open now
Primary completion
2027-12
later than 6 of 11 live
Registered
9th of 13
by date
Lead sponsor
1 of 13
Peking University Third Hospital

Among the 13 studies testing glofitamab in Lymphoma, Mantle-Cell, this one is the 4th largest by planned enrollment, is one of 3 that started in 2025, is one of 9 in phase 2, reaches primary completion later than 6 of the 11 other live ones, and was the 9th registered.

Lymphoma, Mantle-Cell

1,223 studies on the registry are indexed under Lymphoma, Mantle-Cell; 156 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

11 of the 13 studies testing glofitamab in Lymphoma, Mantle-Cell are open now, in 6 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About glofitamab

glofitamab: first FDA approval 2023 (COLUMVI), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 93 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing glofitamab in Lymphoma, Mantle-Cell, or all of them as a file.
02

Study summary

A single-arm, open-label, multi-center clinical study of glofitamab combined with lenalidomide in high risk patients with relapsed or refractory Mantle Cell Lymphoma previously treated with a BTK Inhibitor.

Patients will be eligible if they have received one or more prior lines of therapy, one of which must have been a BTKi. Patients will be enrolled according to a Simon two-stage design, with early stop criteria for lack of efficacy.

Glofitamab will be administered intravenously and lenalidomide will be self-administered orally.

Obinutuzumab pretreatment will be administered intravenously as 2 doses of 1000 mg prior to glofitamab initiation. The primary endpoint is BOR at the end of induction, evaluated by PET/CT according to Lugano criteria during study enrolment.

The primary objective is to evaluate the best objective response rate (BOR) at the end of induction of the combination of glofitamab and lenalidomide.

Read the detailed description

The goal of this clinical study is to evaluate the efficacy of glofitamab combined with lenalidomide in high-risk patients with R/R MCL previously treated with a BTK Inhibitor. The main questions it aims to answer are:

  1. the efficacy of glofitamab combined with lenalidomide in high-risk patients with R/R MCL by best overall response rate (BOR) at the end of induction.
  2. the efficacy of glofitamab combined with lenalidomide in Chinese high-risk patients with R/R MCL, including complete response rate (CRR) at C6 and the end of induction, overall response rate at C6 and the end of induction, best response of complete response (BOCR) .
  3. the safety profiles of Glofitamab combined with lenalidomide in the treatment of high-risk mantle cell lymphoma.
  4. the potential biomarkers which can predict efficacy and safety of Glofitamab combined lenalidomide in Chinese adult patients with relapsed/refractory high risk mantle cell lymphoma, including circulating tumor DNA (ctDNA), total metabolic tumor volume (TMTV), etc.
03

Conditions studied

  • MCL
  • Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Browse trials for

Keywords

  • Relapsed or Refractory MCL, previously treated with a BTK Inhibitor
04

In context

Lymphoma, Mantle-Cell Reclassified

1,223 studies on the registry are indexed under Lymphoma, Mantle-Cell; 156 are open to participants now.

This study's planned enrollment of 43 is above the median of 37 across 1,003 interventional studies indexed under Lymphoma, Mantle-Cell.

Browse Lymphoma, Mantle-Cell studies →

Lead sponsor

Peking University Third Hospital is the lead sponsor of 755 studies on the registry; 275 are open to participants now.

Compared within Lymphoma, Mantle-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Signed Forms

      • Age: >= 18 to 80 years
      • =\< 2
      • Diagnosis of MCL established by histologic assessment
      • Previously treated with at least one for mantle cell lymphoma.
      • Prior therapy have included a BTK inhibitor, including ibrutinib, zanubrutinib, obrutinib, acalabrutinib and various BTKi in clinical trials. BTki exposure is required, which include BTKi failure or intolerance. BTKi failure is defined as progression of disease during BTKi therapy or patients have progressed or after completing BTK inhibitor therapy
      • At least one high risk features as classified:

        • Blastoid/pleomorphic variants ✔ Ki67 ≥50% ✔ TP53 mutation or deletion
        • Bulky disease (defined as any lesion ≥7.5 cm on the screening computed tomography [CT] scan)
        • Patients that did not achieve a CR with their first-line treatment
        • early disease progression (POD24) ✔ patients with relapse and refractory treatment above 3 lines
      • on cross-sectional imaging documented by diagnostic imaging(MRI, CT or PET-CT), (GTD)≥1.5 cm
      • Adequate liver function : Total =\< 3 x (ULN) (unless has Gilbert's disease), (AST) =\< 5.0 x ULN, Alanine aminotransferase (ALT) =\< 5.0 x ULN

Exclusion criteria

Exclusion Criteria:

    • Already enrolled in other Ongoing interventional or non-interventional R/R MCL clinical trials;

      • Currently receiving treatment for other diseases;
      • Previous treatment with lenalidomide;
      • Combined with other malignant tumors within 3 years;
      • The researcher determines that they are not suitable to participate in this study;
      • Serious mental or neurological disorders that affect and/or the expression or observation of adverse reactions;
      • Have a history of major or extensive cardiovascular disease, such as class III or Grade IV heart disease or objective assessment, myocardial infarction, unstable arrhythmia or unstable angina within 6 months before the first cycle;
      • Recent major surgery (within 4 weeks before the start of the first cycle);
      • Active diseases with poor treatment control;
      • Any active infection that may affect the safety of the participant, including bacterial, fungal and various viral infections, occurred within 7 days before the first day of cycle 1;
      • Positive SARS-CoV-2 PCR test within 7 days prior to enrollment
      • Positive test results for chronic infection (defined as positive hepatitis B surface antigen [HBsAg] serology) Participants with occult or prior hepatitis B infection (defined as positive total hepatitis B core antibody and negative HBsAg) may be included if hepatitis B virus (HBV) DNA is undetectable at the time of screening. Such participants must be willing to undergo HBV DNA testing on Day 1 of every cycle and every 3 months for at least 12 months after the final cycle of study treatment and appropriate antiviral therapy as indicated.
      • Positive test results for (hepatitis C virus [HCV] antibody serology testing) Participants positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.
      • A history of severe deep vein thrombosis event or pulmonary embolism within 6 months
      • Patient follow-up was not possible.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (estimated)

Study arms

  • Experimental
    high risk patients with relapsed or refractory Mantle Cell Lymphoma previously treated with a BTKi

    At least one high risk features as classified: * Blastoid/pleomorphic variants ✔ Ki67 ≥50% ✔ TP53 mutation or deletion * Bulky disease (defined as any lesion ≥7.5 cm on the screening computed tomography \[CT\] scan) * Patients that did not achieve a CR with their first-line treatment * early disease progression (POD24) ✔ patients with relapse and refractory treatment above 3 lines

    Drug: Glofitamab · Drug: Lenalidomide

Interventions

  • Glofitamab is a human IgG1-bispecific antibody targeting CD20 expressed on the surface of B cells and CD3ɛ chain expressed on the surface of T cells.

  • Lenalidomide is an agent with immunomodulatory and anti-angiogenic properties which confer multiple antitumor effects.

07

What researchers measure

Primary outcomes

  1. to evaluate the efficacy of glofitamab combined with lenalidomide in high-risk patients with R/R MCL by best overall response rate (BOR) at the end of induction.

    to evaluate the efficacy of glofitamab combined with lenalidomide in high-risk patients with R/R MCL by best overall response rate (BOR) at the end of induction, defined as the percent of patients who achieve a best complete response (CR) or partial response (PR) according to the 2014 Lugano response criteria for non-Hodgkin lymphoma at the end of induction.

    Time frame: 24 months

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR, defined as the proportion of patients with overall response rate at C6 and the end of induction, as determined by the investigator using 2014 Lugano Response Criteria.

    Time frame: up to 24 months

  2. complete response rate (CRR)

    CRR, defined as the proportion of patients with complete response rate(CRR)at C6 and the end of induction, and a best overall response of CR at any time during the studas determined by the investigator using 2014 Lugano Response Criteria.

    Time frame: Up to 24 months

  3. Duration of Response (DoR)

    DoR, defined as the time from the first occurrence of a documented objective response (PR or CR) to disease progression or death from any cause (whichever occurs first) according to the 2014 Lugano Response Criteria, as determined by the investigator.

    Time frame: Up to 48 months

  4. Duration of Complete Response (DoCR)

    DoCR, defined as the time from the initial occurrence of a documented CR until documented disease progression or death due to any cause, whichever occurs first according to the 2014 Lugano Response Criteria, as determined by the investigator.

    Time frame: Up to 48 months

  5. Progression-Free Survival (PFS)

    PFS, defined as the time from the first study treatment to the first occurrence of disease progression or death from any cause (whichever occurs first), as determined by the investigator using 2014 Lugano Response Criteria.

    Time frame: Up to 48 months

  6. Overall Survival (OS)

    OS, defined as the time from the first study treatment to the date of death from any cause.

    Time frame: Up to 48 months

Other outcomes

  1. To evaluate the safety profiles of Glofitamab combined with lenalidomide in the treatment of high-risk mantle cell lymphoma

    List the number and frequency of hematological and non-hematological toxicity (NCI CTCAE v5.0) and calculate the incidence rate.

    Time frame: 48 months

08

Study locations

1 of 1 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2027, 28 months after the start.

Of 154 non-industry phase 2 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 108. This study's planned 28 months is below that.

Counting every sponsor, half of 184 studies reached it within 63 months; a quarter within 38 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2025
First posted
Mar 10, 2026
StartActual
Aug 11, 2025
Primary completionEst.
Dec 30, 2027
CompletionEst.
Dec 30, 2029
Last update
Mar 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07460362
Responsible party
Hongmei Jing (Chief physician, Peking University Third Hospital) — Principal investigator
First posted
Mar 10, 2026
Start date
Aug 11, 2025
Primary completion
Dec 30, 2027 (estimated)
Completion
Dec 30, 2029 (estimated)
Last update
Mar 10, 2026

Study contacts

Hongmei Jing
Contact
hongmei_jing@163.com
86 010-82266781

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Glofitamab · Lenalidomide

Start the discussion